Zansecimab
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2) . Zansecimab has potential applications in angiogenesis and immune regulation[1][2][3].
Product Specifications
CAS Number
[2415205-37-5]
Product Name Alternative
LY-3127804
UNSPSC
12352203
Target
Tie
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/zansecimab.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
[Zansecimab]
Molecular Weight
(145.24 kDa)
References & Citations
[1]Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21 (2) :157-166.|[2]Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
A0859-35H 100 µg
ADAM 17, CT (ADAM17, A Disintegrin and Metalloproteinase Domain 17 (Tumor Necrosis Factor, alpha, Converting Enzyme), CSVP, TACE, cSVP, CD156b, CD156b, MGC71942, TACE, cSVPADAM Metallopeptidase Domain 17, TNF-alpha Converting Enzyme, A Disintegrin and Metalloproteinase Domain 17, A Disintegrin and Metalloproteinase Domain 17 (Tumor Necrosis Factor, alpha, Converting Enzyme), Snake Venom-like Protease)
Ask
View Details 
